Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

T-900607

😃Good
Catalog No. T68147Cas No. 261944-52-9

T-900607 is a novel microtubule protein active agent that disrupts microtubule polymerization through a unique mechanism of action. t-900607 is cardiotoxic.

T-900607

T-900607

😃Good
Purity: 99.98%
Catalog No. T68147Cas No. 261944-52-9
T-900607 is a novel microtubule protein active agent that disrupts microtubule polymerization through a unique mechanism of action. t-900607 is cardiotoxic.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$82In StockIn Stock
5 mg$181In StockIn Stock
10 mg$267In StockIn Stock
25 mg$413In StockIn Stock
50 mg$571In StockIn Stock
100 mg$763In StockIn Stock
200 mg$1,030-In Stock
1 mL x 10 mM (in DMSO)$201In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.98%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity
Description
T-900607 is a novel microtubule protein active agent that disrupts microtubule polymerization through a unique mechanism of action. t-900607 is cardiotoxic.
Targets&IC50
HeLa cells:< 5 μM, MCF-7/ADR cells:< 5 μM
In vitro
t-900607 (compound 5 or VI) showed total growth inhibition for HeLa and MCF-7/ADR cells at<5 μM.[2]
In vivo
t-900607 (15 to 270 mg/m; administered intravenously; advanced and/or metastatic solid malignancies patients; over 30 minutes every 21 days) no DLTs were seen until 270 mg/m, the sixth dose level. The dose was decreased to 180 mg/m with increased cardiac monitoring and at this dose 3/4 of patients experienced cardiac toxicity. The study was reopened at 130 mg/m of 6 enrolled patients, 1 had grade 3 drug-related lethargy considered to be a DLT and this dose was considered the RP2D. No objective responses were seen but stable disease was reported on 7/20. The recommended phase II dose for t-900607 is 130 mg/m given as an intravenous infusion over 60 minutes on a 21-day cycle. Cardiac toxicity was seen with this schedule.[1]
Chemical Properties
Molecular Weight411.3
FormulaC14H10F5N3O4S
Cas No.261944-52-9
SmilesN(S(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F)C2=CC(NC(N)=O)=C(OC)C=C2
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 4.12 mg/mL (10.02 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.4313 mL12.1566 mL24.3132 mL121.5658 mL
5 mM0.4863 mL2.4313 mL4.8626 mL24.3132 mL
10 mM0.2431 mL1.2157 mL2.4313 mL12.1566 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

TubulinMicrotubuleAssociatedMicrotubule Associated
Related Tags: buy T-900607 | purchase T-900607 | T-900607 cost | order T-900607 | T-900607 chemical structure | T-900607 in vivo | T-900607 in vitro | T-900607 formula | T-900607 molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.